0
₹0 0
Nextgen Biotech

Call us:

menu

Erlotero 150mg - Erlotinib Tablets

  • Home
  • Erlotero 150mg - Erlotinib Tablets

Erlotero 150mg - Erlotinib Tablets

Erlotero 150mg is a targeted cancer therapy used to treat non-small cell lung cancer and pancreatic cancer. It works by inhibiting the activity of EGFR (epidermal growth factor receptor), slowing down or stopping cancer cell growth.

Choose Quantity:

-
+
+ Add To Cart
Add to wishlist
Share
Description Product Details
General Information:
Generic Name: Erlotinib
Brand Name: Erlotero
Packing: Strip of tablets
Strength: 150 mg
Manufacturer: Hetero Healthcare
Form: Oral tablet
Category: Tyrosine Kinase Inhibitor (TKI), Antineoplastic agent
Product Intro:
Erlotero 150mg, manufactured by Hetero Healthcare, contains Erlotinib, a tyrosine kinase inhibitor (TKI) used in the treatment of cancers driven by overactive EGFR signaling. It is primarily indicated for NSCLC (non-small cell lung cancer) and metastatic pancreatic cancer, particularly in patients with specific genetic mutations.
Uses:
  1. Non-Small Cell Lung Cancer (NSCLC) – especially EGFR mutation-positive
  2. Advanced or metastatic pancreatic cancer (in combination with gemcitabine)
  3. Maintenance therapy post-chemotherapy in NSCLC
  4. First-line treatment in EGFR-mutated lung cancer
  5. Second-line or later-line treatment for NSCLC patients after chemotherapy
  6. Other EGFR-positive tumors (off-label or investigational uses)
Storage Instructions:
  1. Store at 15–30°C
  2. Protect from moisture and direct sunlight
  3. Keep out of reach of children and pets
How it Works (Mechanism of Action):
Erlotinib is a selective inhibitor of EGFR tyrosine kinase, an enzyme involved in cell growth and proliferation. By blocking EGFR:
  1. It prevents the activation of downstream signaling pathways that promote cancer cell survival
  2. It induces cell cycle arrest and apoptosis in cancer cells
    This targeted approach is particularly effective in tumors with activating EGFR mutations.
Side Effects:
Common Side Effects:
  1. Rash (acne-like)
  2. Diarrhea
  3. Nausea and vomiting
  4. Loss of appetite
  5. Fatigue
  6. Dry skin
Severe Side Effects:
  1. Interstitial lung disease (rare but serious)
  2. Liver enzyme elevation
  3. Gastrointestinal bleeding or perforation
  4. Eye problems (corneal ulceration, conjunctivitis)
  5. Severe skin reactions (Stevens-Johnson syndrome)
Dosage (Typical Recommended Dose):
  1. Standard dose: 150 mg once daily
  2. Dose may vary based on cancer type and patient condition
  3. For pancreatic cancer, 100 mg daily (in combination with gemcitabine)
  4. Adjustments may be needed for liver dysfunction or intolerable side effects
Method of Administration:
  1. Take the tablet at least 1 hour before or 2 hours after a meal
  2. Swallow whole with water
  3. Do not crush, split, or chew the tablet
  4. Take at the same time every day for best results
Precautions:
  1. Perform EGFR mutation testing before starting therapy
  2. Use with caution in patients with liver or kidney impairment
  3. Avoid sun exposure – increases risk of skin toxicity
  4. Monitor liver function and pulmonary status during treatment
  5. Not recommended during pregnancy or breastfeeding
Drug Interactions:
  1. CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampicin) affect blood levels
  2. Proton pump inhibitors and antacids reduce absorption – avoid concurrent use
  3. Interactions with warfarin may increase bleeding risk
  4. Avoid grapefruit juice, which may alter drug metabolism
Allergies:
  1. Contraindicated in patients with known hypersensitivity to Erlotinib
  2. Symptoms of allergic reactions may include:
    1. Hives
    2. Severe rash
    3. Swelling of the face/lips
    4. Difficulty breathing
Overdose Information:
  1. Symptoms may include severe rash, diarrhea, hepatic toxicity, and fatigue
  2. No specific antidote available
  3. In case of overdose, provide symptomatic and supportive care immediately
Missed Dose Instructions:
  1. If missed, take it as soon as you remember
  2. Skip the dose if it’s almost time for the next one
  3. Do not double the dose to catch up
Additional Notes:
  1. Inform your doctor if you have lung issues, liver disease, or GI ulcers
  2. Avoid smoking during treatment – reduces Erlotinib levels and effectiveness
  3. Periodic CT scans and EGFR mutation tests may be needed to assess response
  4. Women of childbearing age should use effective contraception during treatment
View More

In The Same Category

Cart